Annual Report for the FY 2025-26 is herewith enclosed.

A AC U T . S® ACUTAAS CHEMICALS LIMITED A A (Formerly known as Ami Organics Limited) CIN No. : L24100GJ2007PLC051093 You and us: chemistry’s apex August 29, 2026 To, To, The Listing Department, The Listing Department BSE LIMITED, National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, Exchange Plaza, 5™ Floor, Plot no. C-1, Dalal Street, Fort G-Block, Bandra Kurla Complex, Mumbai- 400 001 Mumbai -400051 Scrip Code: 543349 NSE Symbol: ACUTAAS Subject: Annual Report for the Financial Year 2025-26 Pursuant to the provisions of Regulation 30 and Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herewith submit the Annual Report of the Company for the Financial Year 2025-26 along with the Notice convening the 19" Annual General Meeting ("AGM") scheduled to be held on Thursday, September 24, 2026 at 11.30 A.M. (IST) through Video Conferencing/ Other Audio Visual Means in accordance with relevant circulars issued by the Ministry of Corporate Affairs and Securities Exchange Board of India. In compliance with the aforesaid circulars, the Annual Report along with the Notice of the AGM is being sent today, by electronic mode to those shareholders whose e-mail address is registered with the Company/ Registrar and Transfer Agent of the Company /Depository Participants. Also a letter containing the exact path / weblink of the Annual Report of Company for FY 2025-26 is being dispatched to those shareholders whose email id is not registered with the Company/ Registrar and Transfer Agent of the Company /Depository Participants. The Annual Report along with the Notice of the AGM for the Financial Year 2025-26 is also available on the website of the Company at https://acutaas.com/investor/main-annual-report Kindly take the above intimation on record. Yours faithfully, . For, ACUTAAS CHEMICALS LIMITED CS Ekta K. Srivastava Company Secretary & Compliance Officer J Encl: Annual Report for FY 2025-26 - - - . +9175730 15366, +91 72279 77744 Q Registered Office: Plot No. 440/4, 5 & 6, ¢ info@acutaas.com Road No. 82/A, GIDC Sachin, # www.acutaas.com Dist. Surat- 394230, Gujarat, India Focused Diversification. Disciplined Growth. Annual Report 2025-26 Contents Focused Diversification. Disciplined Growth. 02 FY2026 at a Glance 04 Corporate Overview Some companies chase every opportunity in front of them. At Acutaas, we choose Our Key 06 Geographical Presence which ones deserve our chemistry. Business Strategy 08 Our Journey 10 Key Financial Indicators For over two decades, that choice has been guided by a simple, conviction: growth Message from the Chairman that is not earned through discipline is not worth having. It shows up in every & Managing Director 16 Operating Environment decision, which molecule to develop, which geography to enter, which capex Compound Through 18 Value Creation Model rupee to deploy, and it is why a company that began as a single small lab now Innovation stands at the intersection of some of the world’s most demanding industries: Focused Diversification pharmaceuticals, semiconductors, batteries, and specialty chemicals. Where Chemistry meets Conviction Focused diversification is the deliberate act of entering adjacent, high-conviction industries, where 22 Pharmaceutical Intermediates deep process capability, backward integration, and regulatory credibility can be redeployed rather than reinvented. Every vertical is held to the same exacting standard: global-quality 24 Specialty Chemicals certifications, defensible IP, and a genuine right to win. Invest Where the 26 Battery Chemicals Demand Is Proven Disciplined growth is the promise alongside it: capacity built closer to 28 Extending our Global Reach demand but never ahead of contracts, capital committed only where the balance sheet can comfortably absorb it, and every new engine Disciplined Growth nurtured patiently until it has earned its place. Focus gives The Drive Behind the Momentum direction. Discipline gives durability. Together, they are building for the future. 32 Capex Discipline Expand Global 34 Manufacturing Excellence Proximity 36 Research & Development 38 Quality & Compliance 40 People & Culture 42 ESG Snapshot 44 Board of Directors Upgrade the Portfolio Statutory Reports 48 Notice 80 Management Discussion and Analysis 90 Board’s Report 123 Report on Corporate Governance Build New Growth Business Responsibility and Sustainability Engines Report Financial Statements 186 Standalone Financial Statements 238 Consolidated Financial Statements Deepen Pharma Leadership Annual Report CORPORATE STATUTORY FINANCIAL Acutaas Chemicals Limited 2025-26 OVERVIEW REPORT STATEMENTS FY26 at a Glance Focused, Financial Operational ESG Highlights Highlights Highlights Disciplined, (Consolidated) Delivered H13,394 610 + 16 MW Products across four Renewable energy Revenue from Operations FY26 was a year in which Acutaas's core ( 33% y-o-y) business verticals capacity installed pharmaceutical business, our emerging CDMO franchise, and its early-stage H3,564 1,000 + Zero battery and semiconductor bets all Employees Safety-related incidents Profit After Tax moved in an upward direction. ( 122% y-o-y) ~55 Zero Countries Regulatory incidents H4,804 ~600 85 % Customers Total waste recycled EBITDA (through GPCB approved ( 107% y-o-y) recyclers) 130 ~8,000 R&D team members CSR beneficiaries 5 EcoVadis Platinum Manufacturing facilities (the fifth is under Placing Acutaas in the top construction in South Korea) 1% of rated companies globally (August 2025) Key Talking Points of the Year Diversification Beyond Pharma Capex Discipline The South Korea Expansion Our People and Value Creation Intermediates Running through every new initiative is one rule: capital gets A significant part of this year’s story sits outside India altogether. Our human and financial sides exist together: a workforce of Specialty chemicals have grown from just 1% of revenue in FY2019 deployed only against demand that is already contracted or visible. The ~I2,000 Million invested in the Indichem Inc. joint venture over 1,000 people, entrepreneurial by design, sitting behind a to 12% in FY2026. As we move ahead, lower-margin commodity Our H10,000+ million programme spans FY2023 to FY2030, which gives Acutaas a live R&D centre and an under-construction year that delivered our highest-ever RoCE of 39.3%, and creating lines are being steadily replaced with harder-to-qualify, better- is why FY2026’s I1,950 Million spend went almost entirely towards manufacturing base in South Korea—our first genuine operating value for employees, shareholders and stakeholders alike. realising products in battery additives, semiconductor chemicals, projects already backed by customer commitments. foothold inside a major global semiconductor hub. and other specialty chemicals. 02 03 Annual Report CORPORATE STATUTORY FINANCIAL Acutaas Chemicals Limited 2025-26 OVERVIEW REPORT STATEMENTS Corporate Overview Chemistry That Powers Better Living Every molecule we develop serves a larger purpose. By combining scientific excellence with disciplined expansion into future-focused markets, Acutaas is building a diversified chemistry platform that creates lasting value for customers, industries and society. Our Mission Acutaas Chemicals Limited (formerly Ami Organics Limited) is a Gujarat- headquartered, multi-vertical specialty chemicals company built on over 22 years At Acutaas, we aspire to be a globally integrated pharmaceutical of process chemistry expertise supported by cutting edge technology platform. intermediates and specialty chemicals company, driven by focusing We started as a single innovator-molecule business and have now evolved on three key areas: sustainable innovation, unparalleled quality, and into a diversified platform spanning advanced pharmaceutical intermediates, pioneering technology. semiconductor chemicals, battery chemicals, and commodity chemicals, each backed by deep backward int [Showing first 8,000 characters — download PDF for full document]